In the phase 3 LIBERTY study, the investigational monoclonal antibody, VYD2311, had significantly fewer adverse events than an mRNA COVID-19 vaccine, and it did not blunt vaccine-induced neutralizing titers when the two were given together.
|Articles|June 20, 2023
Innovative ABNCoV2 COVID-19 Booster Vaccine Induces Long-Lasting Protection
Author(s)Nina Cosdon
ABNCoV2, a non-adjuvanted COVID-19 booster vaccine by Bavarian Nordic, demonstrates promising results in phase 2 trials. The vaccine generates strong immune responses, neutralizing multiple variants of concern, including Beta, Delta, and Omicron.
Advertisement
This week, the fully integrated vaccines company Bavarian Nordic
ABNCoV2 is a non-adjuvanted, investigational
Investigators recruited 36 participants, none of whom had previously received a COVID-19 booster shot. The participants had no reports of COVID-19 infection, nor positive PCR results for SARS-CoV-2 since vaccination in the study.
A year after booster vaccination with ABNCoV2, participants retained high levels of neutralizing antibodies, at more than 90%. A separate analysis of 40 participants enrolled in the trial were tested against Omicron XBB.1.1. At 2 weeks after vaccination, the ABNCoV2 booster induced neutralizing antibodies against XBB.1.1 in 43% of study patients.
“It is encouraging to see durable antibody levels against the earlier variants of concern 1 year after vaccination with ABNCoV2, that has not been shown for other COVID19 vaccines,” said Paul Chaplin, president and CEO of Bavarian Nordic. “While it is believed that the currently circulating XBB variants are less virulent, the weakened immune responses against this more distant variant is a concern and needs to be carefully evaluated in the ongoing Phase 3 trial.”
A double-blind, controlled, phase 3 trial was initiated in September 2022. The primary trial endpoint was to determine the noninferiority of ABNCoV2 compared to the
Bavarian Nordic is focused on vaccine research, development, manufacturing, and commercialization. The company worked with the US government to develop smallpox and
Advertisement
Related to this article
As the Bundibugyo virus outbreak in the Democratic Republic of the Congo surpasses 9300 confirmed cases and 4400 deaths, this FAQ explains how the virus spreads, how it presents, why it is hard to diagnose and treat, which vaccines and therapies are being tested, and why CDC considers the risk to the United States low.
Projected disease burden from declining childhood vaccine coverage shows increases in vaccine-preventable diseases. Benjamin Lopman, PhD, provides insights on how VaxImpactMap works and the potential long-term disease consequences of decreased immunization rates.
A 39-year-old unvaccinated Franklin County woman has died after a recent measles diagnosis. Nationally, numbers continue to increase and the US has passed 4,000 cases.
The National Foundation for Infectious Diseases (NFID) recently held its respiratory season kick-off, which included the release of its annual respiratory disease survey. This year, the survey revealed the gap between vaccine support and uptake. Robert Hopkins Jr, MD, medical director of NFID delves deeper into the findings of the survey and the vaccine uptake challenges associated with certain immunizations.
The latest CDC numbers show a 5.0% increase of measles cases from week-to-week. The US total reached 4080 confirmed cases, 78% above all of 2025.
With US measles cases nearing 3,900 this year and Pennsylvania reporting its fifth measles-related death, here is a review of how the virus spreads, how it is prevented and managed, and what severe disease looks like.
Vaxcyte's 31-valent pneumococcal conjugate vaccine candidate met every prespecified primary immunogenicity and safety endpoint against PCV20 and PCV21 in the OPUS-1 trial of 4,047 US adults.
Advertisement
Advertisement